ArticleThe Journal of urology2022
Survival Impact of Variant Histology Diagnosis in Upper Tract Urothelial Carcinoma.
Article in The Journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Association of molecular subtypes based on GATA3, KRT5, and P16 expression with clinicopathological features and prognosis in upper tract urothelial carcinoma.World journal of urology · 2026Article
- Micropapillary variant of upper tract urothelial carcinoma: a SEER-based propensity score-matched analysis of clinicopathological features and survival outcomes.International urology and nephrology · 2026Article
- Genomic Characterization of Urothelial Carcinoma and Sarcomatoid Carcinoma of the Upper Urinary Tract.Cancers · 2026Article
- Divergent Differentiation and Histologic Subtypes in Upper Tract Urothelial Carcinoma Demonstrate Distinct Patterns of Extraurothelial Recurrence.European urology open science · 2026Article
- Expression and prognostic significance of INSM1 compared with traditional neuroendocrine markers in mixed urothelial and small-cell carcinoma of the renal pelvis.Frontiers in oncology · 2026Article
- Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.Discover oncology · 2025Review
- Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.American journal of clinical pathology · 2025Article
- PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.Cancer · 2024Article
- Evaluation of histological variants of upper tract urothelial carcinoma as prognostic factor after radical nephroureterectomy.World journal of urology · 2024Article
- Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective study.Translational andrology and urology · 2024Article
- A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.The journal of pathology. Clinical research · 2024Article
- Preoperative Systemic Inflammation Score Predicts the Prognosis of Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.Journal of clinical medicine · 2024Article
- Article
- The impact of histological variants in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.Journal of cancer research and clinical oncology · 2023Article
- Optimization of postoperative surveillance protocols in upper tract urothelial cancer: A retrospective cohort study.Frontiers in oncology · 2023Article
- Urothelial carcinoma: Perioperative considerations from top to bottom.CA: a cancer journal for cliniciansReview
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeLittle is known regarding the prognostic implications of variant histology in upper tract urothelial carcinoma (UTUC). We sought to evaluate the impact of variant histology UTUC on patient survival outcomes at our institution. MATERIALS AND
methodsWe identified 705 patients who underwent nephroureterectomy for UTUC at our institution between January 1995 and December 2018. We tested the association between variant histology and cancer-specific survival (CSS) and overall survival (OS) using separate multivariable Cox models after adjusting for pathological stage.
resultsForty-seven patients (6.7%) had variant histology, with prevalence increasing over time (p=0.003). Other demographic and surgical characteristics were similar between variant histology and pure urothelial carcinoma groups. While patients with variant histology were more likely to receive neoadjuvant chemotherapy (38% vs 15%, p <0.001), they were also more likely to have a higher pathological T stage (p <0.001). Variant histology was associated with significantly worse CSS (HR: 2.14; 95% CI 1.33, 3.44; p=0.002) and OS (HR: 1.74; 95% CI 1.15, 2.63; p=0.008). After adjusting for pathological T stage, variant histology was not significantly associated with CSS (HR: 1.17; 95% CI 0.72, 1.89; p=0.5) or OS (HR: 1.20; 95% CI 0.79, 1.84; p=0.4).
conclusionsVariant histology UTUC is associated with advanced stage and poor survival, and could serve as a useful biomarker for high-risk disease when pathological stage is unknown. However, the inferior CSS and OS with variant histology can be explained by the higher tumor stage on nephroureterectomy. Thus, finding variant histology on surgical pathology does not provide additional prognostic information beyond stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.